These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18290706)

  • 1. [Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
    Barreales M; Castellano G; Fernández I; Muñoz R; Manzano M; Solís Herruzo JA
    Rev Esp Enferm Dig; 2007 Dec; 99(12):738-40. PubMed ID: 18290706
    [No Abstract]   [Full Text] [Related]  

  • 2. [Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
    Izumi N; Kurosaki M; Suzuki S; Tamaki N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2108-11. PubMed ID: 23221060
    [No Abstract]   [Full Text] [Related]  

  • 3. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
    Dai CY; Huang CF; Chuang WL; Huang JF; Yu ML
    Am J Gastroenterol; 2009 Sep; 104(9):2358-9. PubMed ID: 19727098
    [No Abstract]   [Full Text] [Related]  

  • 4. [New therapeutic agents for chronic hepatitis C].
    Hiramatsu N; Hayashi N
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):170-7. PubMed ID: 14968593
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress on the treatment of hepatitis C.
    Nierengarten MB
    Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment].
    Hiramatsu N
    Nihon Naika Gakkai Zasshi; 2008 Jan; 97(1):75-81. PubMed ID: 18360974
    [No Abstract]   [Full Text] [Related]  

  • 7. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
    Hrachovec J; Patel P
    Gastroenterology; 2003 Jun; 124(7):2003-4; author reply 2004-5. PubMed ID: 12812198
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
    Kim DY
    Gut Liver; 2014 Jul; 8(4):335-6. PubMed ID: 25071896
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
    Sagir A; Wettstein M; Heintges T; Häussinger D
    Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
    [No Abstract]   [Full Text] [Related]  

  • 10. [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
    Han KH; Yoon YH
    Korean J Hepatol; 2004 Jun; 10(2):81-7. PubMed ID: 15218341
    [No Abstract]   [Full Text] [Related]  

  • 11. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Santin M; Shaw E
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Picon PD; Costa AF; Kuchenbecker R; Beltrame A
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
    [No Abstract]   [Full Text] [Related]  

  • 14. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
    Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
    J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Cecil BD
    Lancet; 2002 Jan; 359(9302):263-4. PubMed ID: 11812598
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Pearlman BL; Ehleben C
    Hepatology; 2010 Oct; 52(4):1519-20; author reply 1520-1. PubMed ID: 20879035
    [No Abstract]   [Full Text] [Related]  

  • 17. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
    [No Abstract]   [Full Text] [Related]  

  • 18. [Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
    Hokari A
    Nihon Rinsho; 2011 May; 69 Suppl 4():196-200. PubMed ID: 22096918
    [No Abstract]   [Full Text] [Related]  

  • 19. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
    Hadziyannis SJ; Sette H; Morgan TR; Balan V; Diago M; Marcellin P; Ramadori G; Bodenheimer H; Bernstein D; Rizzetto M; Zeuzem S; Pockros PJ; Lin A; Ackrill AM;
    Ann Intern Med; 2004 Mar; 140(5):346-55. PubMed ID: 14996676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response to interferon therapy using mutations in the HCV-NS5A].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2011 May; 69 Suppl 4():234-8. PubMed ID: 22096925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.